Ultragenyx Pharmaceutical Inc. (RARE) is a publicly traded Healthcare sector company. As of May 21, 2026, RARE trades at $24.00 with a market cap of $2.38B and a P/E ratio of -3.82. RARE moved +4.14% today. Year to date, RARE is +1.13%; over the trailing twelve months it is -37.43%. Its 52-week range spans $18.29 to $58.00. Analyst consensus is strong buy with an average price target of $48.86. Rallies surfaces RARE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ultragenyx Q1 Loss Widens as Crysvita Sales Falter, Evkeeza and Dojolvi Rise: Ultragenyx reported a Q1 loss wider than analysts’ forecasts, driven by a seasonal Crysvita sales decline despite partial offset from Evkeeza and Dojolvi revenue growth. CFO Howard Horn and IR VP Joshua Higa will present at Bank of America’s Healthcare Conference on May 12 at 2:20 PM PT.
| Metric | Value |
|---|---|
| Price | $24.00 |
| Market Cap | $2.38B |
| P/E Ratio | -3.82 |
| EPS | $-6.10 |
| Dividend Yield | 0.00% |
| 52-Week High | $58.00 |
| 52-Week Low | $18.29 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $669.71M |
| Net Income | $-608.92M |
| Gross Margin | 0.00% |
15 analysts cover RARE: 0 strong buy, 13 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $48.86.